| چکیده انگلیسی مقاله |
Background: The aim of this study was to conduct a meta-analysis to estimate the association between the two SNPs and PCa risk. Methods: Medline, Embase, Scopus, PubMed, Web of Science, Wan Fang Database and Chinese Zhi Wang Database were searched for the association of the two SNPs with susceptibility to PCa. The effect size was pooled by odds ratios (ORs) and 95% confidence intervals (95% CIs). Results: Nine case-control studies, 5 on rs3787016 and 4 on rs2910164, were included. As regards rs3787016, an increased risk of PCa was identified in all genotype models (T versus C: OR = 1.18, 95% CI 1.11-1.25; CT versus CC: OR = 1.17, 95% CI 1.08-1.26; TT versus CC: OR = 1.41, 95% CI 1.22-1.63; TT + CT versus CC: OR = 1.20, 95% CI 1.12-1.30; TT versus CT + CC: OR = 1.32, 95% CI 1.15-1.52). However, no significant association was found between rs2910164 and PCa risk in any genetic models, in fact a trend of reduced risk could be seen (C versus G: OR = 0.91, 95% CI 0.79-1.05; GC versus GG: OR = 0.93, 95% CI 0.74-1.18; CC versus GG: OR = 0.70, 95% CI 0.47-1.02; CC + GC versus GG: OR = 0.90, 95% CI 0.73-1.12; CC versus GC + GG: OR = 0.78, 95% CI 0.56-1.08). Besides, in analysis of subgroups by source of controls, the decreased results were observed in studies using population-based controls. Conclusion: lncRNA POLR2E polymorphism rs3787016 is associated with a significantly increased risk of PCa, while a trend of reduced risk appears with mir-146a polymorphism rs2910164. |
| نویسندگان مقاله |
| Shuaishuai HUANG
Laboratory of Kidney Carcinoma, Urology and Nephrology Institute of Ningbo University, Ningbo Urology and Nephrology Hospital, Ningbo, Zhejiang 315000, China
| Hui CUI
Laboratory of Kidney Carcinoma, Urology and Nephrology Institute of Ningbo University, Ningbo Urology and Nephrology Hospital, Ningbo, Zhejiang 315000, China
| Zhongguan LOU
Laboratory of Kidney Carcinoma, Urology and Nephrology Institute of Ningbo University, Ningbo Urology and Nephrology Hospital, Ningbo, Zhejiang 315000, China
| Xue WANG
Laboratory of Kidney Carcinoma, Urology and Nephrology Institute of Ningbo University, Ningbo Urology and Nephrology Hospital, Ningbo, Zhejiang 315000, China
| Liangliang CHEN
Laboratory of Kidney Carcinoma, Urology and Nephrology Institute of Ningbo University, Ningbo Urology and Nephrology Hospital, Ningbo, Zhejiang 315000, China
| Zhenhua XIE
Laboratory of Kidney Carcinoma, Urology and Nephrology Institute of Ningbo University, Ningbo Urology and Nephrology Hospital, Ningbo, Zhejiang 315000, China
| Michael HEHIR
Dept. of Medical School, Ningbo University, Ningbo, Zhejiang 315211, China
| Xuping YAO
Laboratory of Kidney Carcinoma, Urology and Nephrology Institute of Ningbo University, Ningbo Urology and Nephrology Hospital, Ningbo, Zhejiang 315000, China
| Yu REN
Laboratory of Kidney Carcinoma, Urology and Nephrology Institute of Ningbo University, Ningbo Urology and Nephrology Hospital, Ningbo, Zhejiang 315000, China
| Dong CEN
Laboratory of Kidney Carcinoma, Urology and Nephrology Institute of Ningbo University, Ningbo Urology and Nephrology Hospital, Ningbo, Zhejiang 315000, China
| Guobin WENG
Laboratory of Kidney Carcinoma, Urology and Nephrology Institute of Ningbo University, Ningbo Urology and Nephrology Hospital, Ningbo, Zhejiang 315000, China
|